INFORMATION DISCLOSURE  P HATEMENT BY APPLICANT			ATTY. DOCKET NO. 102392-200			SERIAL NO: 10/627,014		
0, 443			APPLICANT: ANTHONY H. CINCOTTA					
иоv 1 9 2007 ළ			FILING DATE: July 25, 2003			GROUP: 1617		
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL*	DOCUMENT NUMBER	DATE	NAME CLAS		CLASS	SUBCLASS	FILING DATE IF APPROPR.	
						<u> </u>		
					,			
						<del> </del>		
<u> </u>								
	FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS		SUBCLASS	TRANSLATION Yes No	
	WO 97/41873	11/13/1997	PCT	A61K		31/58		
						<del></del>		
	OTHER DOC	UMENTS (INCLUD	DING AUTHOR, TITLE	, DATE, PERTINE	ENT PAC	GES, ETC.)		
	CINCOTTA, ANTHONY H., ET AL., "Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes", EXPERT OPINION ON INVESTIGATIONAL DRUGS, Ashley Publications Ltd., United Kingdom, Vol. 8, No. 10, Pages 1683-1707 (1999); XP002453155.							
	PIJL, H and MEINDER, E.A., "Modulation of monoaminergic neural circuits: Potential for the treatment of type 2 diabetes mellitus", DATABASE EMBASE [Online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, Treatments in Endocrinology, Vol. 1, No. 2, Pages 71-78 (2002); XP002453157.							
EXAMINER:	INER: DATE CONSIDERED:							
*EXAMINER: Initi	*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not							

<sup>\*</sup>EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \\15546\5\679493.1